Mirati Therapeutics, Inc. (MRTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 54.26 |
| Open | 53.11 |
| Bid | 51.00 x 800 |
| Ask | 58.30 x 900 |
| Day's Range | 51.64 - 53.55 |
| 52 Week Range | 32.96 - 124.81 |
| Volume | |
| Avg. Volume | 2,002,244 |
| Market Cap | 3.027B |
| Beta (5Y Monthly) | 0.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.96 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 115.50 |
- PR Newswire
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 4 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
- PR Newswire
Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate in two upcoming healthcare conferences.
- Zacks
Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage
Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate phase I/II study in early 2023.
